FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
On March 13, 2019, Fennec Pharmaceuticals Inc. issued a news release announcing the fourth-quarter and full-year financial results for the period ended December 31, 2018. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit 99.1 | Press Release dated March 13, 2019 |
FENNEC PHARMACEUTICALS INC. Exhibit
EX-99.1 2 tv516205_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS ·Initiated rolling New Drug Application to U.S. FDA for PEDMARKTM ·Secured $12. 5 million debt financing to support a potential commercial launch ·Strong financial position with $22.8 million in cash and no debt ·Targeted commercial launch in 2020 Research Triangle Park,…
To view the full exhibit click here
About FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF)
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.